|
|
News Breaks
|
November 19, 2009
|
| 16:17 EDT |  | SCMP |
| theflyonthewall.com: | Sucampo receives authorization in Switzerland for Amitiza constipation medicine | | Sucampo Pharma Europe, a subsidiary of Sucampo Pharmaceuticals, announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a marketing authorization for Amitiza, lubiprostone, 24 microgram gel capsules for the long-term treatment of patients with chronic idiopathic constipation, or CIC. This is the first European regulatory approval for Sucampo and Amitiza is the first prescription medicine to be approved in Switzerland for the long-term treatment of CIC. Amitiza is already approved by the U.S. FDA for the long-term treatment of CIC in adults and for the treatment of irritable bowel syndrome with constipation, or IBS-C, in adult women. Amitiza is the only prescription medicine approved by the FDA for either of these indications. :theflyonthewall.com |
|
|
News For SCMP From The Last 14 Days Check below for free stories on SCMP the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 2, 2012
|
| 05:25 EDT | | SCMP |
| theflyonthewall.com: | Sucampo's Lubiprostone meets primary endpoint in Phase 3 clinical trial for OBD | | Sucampo Pharmaceuticals and Takeda Pharmaceuticals U.S.A., Inc. announced that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction, or OBD, in patients with chronic, non-cancer pain, excluding those taking methadone. :theflyonthewall.com |
|
|
|
|
|
